BI-847325|cas 1207293-36-4|DC Chemicals

BI-847325|cas 1207293-36-4|DC Chemicals

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

Product Name: BI-847325 |Catalog Number: DC8401 |CAS 1207293-36-4 |Other names: BI-847325,BI 847325,BI847325 |Chemical Name: (Z)-3-(3-((4-((dimethylamino)methyl)phenylamino)(phenyl)methylene)-2-oxoindolin-6-yl)-N-ethylpropiolamide |Molecule Formular: C29H28N4O2 |MW: 464.56

BI-847325 shows growth-inhibitory effects on BRAF-mutant and vemurafenib-resistant melanoma cells with IC50 ranging from 0.3 nM to 2 μM, and prevents colony formation in six BRAF-mutant melanoma cell lines. BI-847325 also induces apoptosis by reducing Mcl-1 expression. [1]In mice bearing 1205Lu and 1205LuR xenografts, BI-847325 (75 mg/kg, p.o.) causes significant tumor suppression without significant alteration in the body weights. [1] For the detailed information of BI-847325, the solubility of BI-847325 in water, the solubility of BI-847325 in DMSO, the solubility of BI-847325 in PBS buffer, the animal experiment (test) of  BI-847325, the cell expriment (test) of BI-847325, the in vivo, in vitro and clinical trial test of BI-847325, the EC50, IC50,and affinity,of BI-847325, For the detailed information of BI-847325, the solubility of BI-847325 in water, the solubility of BI-847325 in DMSO, the solubility of BI-847325 in PBS buffer, the animal experiment (test) of  BI-847325, the cell expriment (test) of BI-847325, the in vivo, in vitro and clinical trial test of BI-847325, the EC50, IC50,and affinity,of BI-847325, Please contact DC Chemicals.

For research and scientific purpose only, not for human use.